Regulation (EC) No 273/2004 of the European Parliament and of the CouncilShow full title

Article 14 U.K. Implementation

[F1 Where necessary, the Commission shall adopt implementing measures concerning the following:]

[F2 The measures referred to in points (a) to (e) of the first paragraph, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 15(3).

The measures referred to in point (f) of the first paragraph shall be adopted in accordance with the management procedure referred to in Article 15(2).]

(a)

determination of the requirements and conditions for the granting of the licence as provided for in Article 3 and the details pertaining to the licence;

(b)

determination, whenever necessary, of the conditions which shall apply to the documentation and labelling of mixtures and preparations containing substances listed in Annex I, as provided for in Articles 5 to 7;

(c)

any amendments to Annex I made necessary by amendments to the tables in the Annex to the United Nations Convention;

(d)

amendments to the thresholds set in Annex II;

(e)

determination of the requirements and conditions for customer declarations referred to in Article 4, as well as the detailed rules concerning their use. This shall include rules on how to provide customer declarations in electronic form, where appropriate;

(f)

other measures needed for the efficient implementation of this Regulation.

Textual Amendments

F1 Substituted by Regulation (EU) No 1258/2013 of the European Parliament and of the Council of 20 November 2013 amending Regulation (EC) No 273/2004 on drug precursors (Text with EEA relevance).

F2 Inserted by Regulation (EU) No 1258/2013 of the European Parliament and of the Council of 20 November 2013 amending Regulation (EC) No 273/2004 on drug precursors (Text with EEA relevance).